Pre-market
Loading markets…

Advertisement

Stocks

Why Synopsys stock plummeted yesterday

By Wealth Awesome -
Stocks & ETFs:SNPS.US

Get SNPS.US alerts:

Photos provided by Pexels

Synopsys Inc. faced significant losses as shares dropped sharply in the latest trading session.

Shares of Synopsys Inc. (SNPS) fell 5.40% yesterday, closing at CA$393.84. This decline is part of a broader trend of underperformance for the company, which has seen its stock down 29% over the past year.

Advertisement

Investor takeaway: Despite strong financial results and a raised outlook, Synopsys' recent layoffs and restructuring efforts have raised concerns among investors, leading to a notable drop in stock price.

5.40% decline in Synopsys stock yesterday

The stock's decline reflects ongoing concerns about the impact of layoffs and restructuring on future growth.

Bull case

Synopsys has shown solid financial performance, with year-over-year growth in revenue and earnings. Analysts still have a 'Buy' rating, suggesting there’s potential for recovery.

Bear case

The recent layoffs and restructuring, along with a history of underperformance compared to industry peers, raise questions about the company's future growth prospects.

Recent Layoffs Impact Investor Sentiment

Advertisement

Synopsys announced plans to eliminate 128 positions at its Sunnyvale campus, mainly affecting engineering and R&D teams. This decision is part of a broader restructuring initiative following the company's $35 billion acquisition of Ansys. While management claims these layoffs aim to improve operational efficiency, investors reacted negatively, leading to a significant drop in stock price.

Financial Performance vs. Market Reaction

Despite reporting strong financial results, including a 42.4% year-over-year revenue increase in Q3 FY2026, Synopsys' stock has struggled to maintain momentum. Analysts had raised their full-year revenue outlook, indicating strong demand for EDA solutions. However, the market's focus on the layoffs and restructuring has overshadowed these positive developments, resulting in a decline in investor confidence.

Analyst Outlook Remains Positive

Even with the recent stock decline, analysts maintain a positive outlook for Synopsys, with a consensus rating of 'Strong Buy' and a mean price target suggesting a potential 32.5% upside. This optimism is based on the company's strong financial performance and the increasing complexity of semiconductor design, which is expected to drive demand for Synopsys' products in the long term.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: September 8, 2026
Last Updated: September 8, 2026
PARTNER SPOTLIGHT

Blue Cross Life® Term Life Insurance

Affordable term life coverage in Canada — get a free quote in seconds, no credit card required.

  • Coverage from $100,000 to $5 million, terms of 10–30 years
  • 10% off first-year premiums when couples apply together
  • Fully digital application — many qualify without a medical exam

Sponsored links

Advertisement